EN DE
Watch ImmunoPrecise Antibodies Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ImmunoPrecise Antibodies Ltd. (HYFT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of ImmunoPrecise Antibodies Ltd. stock $0.69, price $0.94, that is 26.4% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA6026871054

IA ImmunoPrecise Antibodies Ltd. logo Thin data Nov 17, 2026

ImmunoPrecise Antibodies Ltd.

HYFT · US

Expensive (fair value 26% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Revenue last quarter +21% vs. a year ago. 
Quality 42/100 
Fair value $0.6899 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −3.1 %/yr in CAD) 
Loss-making · -105.2% net margin (TTM) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch ImmunoPrecise Antibodies Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.59 $0.3290 Fair Value $0.6899 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.3290 – $7.59 · fair‑value band $0.5174 – $0.8624 · the $0.9378 price screens above the $0.6899 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow ImmunoPrecise Antibodies in your weekly email

Every Wednesday you see whether ImmunoPrecise Antibodies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics.

Show moreShow less

The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities.

The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Stock analysis

ImmunoPrecise Antibodies Ltd. (HYFT) currently trades at $0.9378, while our estimate is $0.6899, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5174 (bear) to $0.8624 (bull), the price of $0.9378 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ImmunoPrecise Antibodies Ltd. reported revenue of C$15.3M in FY2026 versus C$19.4M in FY2022, a compound −5.7%/yr. Reported net income was −C$13.7M in FY2026.

Key figures

Market cap $44.6M Micro · P/S ratio 3.31 · EPS (TTM) $−0.2600 · Net margin −89.7% · Return on equity −124% · Return on assets (EBIT) −34.0% (5-year average) · Operating margin −160% · Revenue (TTM) C$16.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, HYFT screens richer than that median.

Fair Value

Bear $0.5174 Fair Value $0.6899 Bull $0.8624
Price $0.9378 · Downside -26.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−37.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Start year 2021 (pandemic). Over 10 years: +23.2% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−23.3% (2021) → −96.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

HYFT screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ImmunoPrecise Antibodies Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −26.4% · Below median
Profitability
Return on assets −64.4% · Bottom 25%
Net margin (12 months) −105.2% · Bottom 25%
Operating margin (12 months) −159.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 21.3% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.44× · Priciest 25%
P/S (12 months) 3.93× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs HYFT
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs HYFT
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs HYFT
argenx SE ARGX $950.95 $908.40 −4% vs HYFT
CSL Limited CSL A$199.55 A$186.49 −7% vs HYFT
Moderna, Inc MRNA $215.27 $135.64 −37% vs HYFT
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs HYFT
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs HYFT
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs HYFT
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs HYFT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ImmunoPrecise Antibodies Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ImmunoPrecise Antibodies Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/HYFT

Frequently asked questions

Is ImmunoPrecise Antibodies Ltd. (HYFT) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $0.6899 versus a price of $0.9378, about 26% lower (overvalued).
What is the fair value of HYFT?
Our estimate for ImmunoPrecise Antibodies Ltd. is $0.6899 (as of Nov 17, 2026), built from audited fundamentals. The current price: $0.9378.
What is the quality score of HYFT?
ImmunoPrecise Antibodies Ltd. has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ImmunoPrecise Antibodies Ltd. (HYFT)?
Our calculated price target is the estimate of $0.6899 (as of Nov 17, 2026). Cautious scenario $0.5174, optimistic scenario $0.8624. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ImmunoPrecise Antibodies Ltd. stock forecast for 2026?
Our estimate puts fair value at $0.6899, about 26% lower versus a price of $0.9378 (overvalued). Cautious scenario $0.5174, optimistic scenario $0.8624. The calculation is refreshed regularly with new filings.
What is the revenue of ImmunoPrecise Antibodies Ltd. (HYFT)?
ImmunoPrecise Antibodies Ltd. reported trailing-twelve-month revenue of about C$16.2M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of ImmunoPrecise Antibodies Ltd. (HYFT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ImmunoPrecise Antibodies Ltd. it is $0.6899 per share (as of Nov 17, 2026), against a price of $0.9378.
Is ImmunoPrecise Antibodies Ltd. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, HYFT trades above its calculated fair value: price $0.9378, fair value $0.6899, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HYFT?
No. The price is what the market pays today ($0.9378); the fair value is what the company's own numbers justify ($0.6899). For ImmunoPrecise Antibodies Ltd. the two are $0.2479 per share apart. That gap is exactly why we show both numbers side by side.
How much is ImmunoPrecise Antibodies Ltd. worth?
The market values ImmunoPrecise Antibodies Ltd. at about $44.6M (market capitalisation, as of Nov 17, 2026). Per share that is $0.9378; our models calculate a fair value of $0.6899 per share.
What do the bullish and bearish scenarios say about HYFT?
Our models span a range for ImmunoPrecise Antibodies Ltd.: cautious scenario $0.5174, base $0.6899, optimistic $0.8624 per share (as of Nov 17, 2026, price $0.9378). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ImmunoPrecise Antibodies Ltd. (HYFT)?
Balance-sheet figures for ImmunoPrecise Antibodies Ltd. (as of Nov 17, 2026): return on equity −123.7%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is HYFT from its 52-week high?
ImmunoPrecise Antibodies Ltd. trades at $0.9378, about 66% below its 52-week high of $2.78 and at the low of $0.9378 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6899 is for.
Which stocks are comparable to ImmunoPrecise Antibodies Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ImmunoPrecise Antibodies Ltd. stock attractive at the current price?
The data as of Nov 17, 2026: price $0.9378, calculated fair value $0.6899 (−26%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. ImmunoPrecise Antibodies Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ImmunoPrecise Antibodies Ltd. (HYFT)?
The closing price on Nov 16, 2026 was $0.9378. Our estimate is $0.6899, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ImmunoPrecise Antibodies Ltd. right now?
The price sits above even our optimistic bull case ($0.8624). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of ImmunoPrecise Antibodies Ltd.

How large is the market capitalisation of ImmunoPrecise Antibodies Ltd. (HYFT)?
The market capitalisation of ImmunoPrecise Antibodies Ltd. is $44.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ImmunoPrecise Antibodies Ltd. (HYFT)?
The price-to-sales ratio of ImmunoPrecise Antibodies Ltd. is 3.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ImmunoPrecise Antibodies Ltd. (HYFT)?
Earnings per share at ImmunoPrecise Antibodies Ltd. are $−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ImmunoPrecise Antibodies Ltd. (HYFT)?
The net margin of ImmunoPrecise Antibodies Ltd. is −89.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ImmunoPrecise Antibodies Ltd. (HYFT)?
The return on equity (ROE) of ImmunoPrecise Antibodies Ltd. is −124% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ImmunoPrecise Antibodies Ltd. (HYFT)?
On an EBIT basis the return on assets of ImmunoPrecise Antibodies Ltd. is −34.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ImmunoPrecise Antibodies Ltd. (HYFT)?
The operating margin of ImmunoPrecise Antibodies Ltd. is −160% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ImmunoPrecise Antibodies Ltd. (HYFT)?
Revenue at ImmunoPrecise Antibodies Ltd. is growing 21.3% versus a year earlier (3y avg −9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ImmunoPrecise Antibodies Ltd. (HYFT) generate?
The free cash flow of ImmunoPrecise Antibodies Ltd. is −C$12.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ImmunoPrecise Antibodies Ltd. (HYFT) hold?
ImmunoPrecise Antibodies Ltd. holds more cash than debt, C$7.8M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ImmunoPrecise Antibodies Ltd. in the live analysis

One click puts ImmunoPrecise Antibodies Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.